Deals this week: Selecta Biosciences, bluebird bio, TransGenic
Selecta Biosciences intends to raise $50m through private placement of shares of its common stock to be subscribed to by new and existing institutional investors and one of the company’s board of directors.
Proceeds will be used for ongoing clinical development of SEL-212, the company’s candidate for the treatment of chronic severe gout, and to bring additional product candidates to clinical development.
bluebird bio has offered 3.81 million shares of its common stock at a price of $105 each in a public offering to raise gross proceeds of $400.05m.
Proceeds will be used to co-develop and co-promote bb2121 product candidate for the planned Phase I clinical study of bb21217 product candidate and for other research and development purposes.
TransGenic and Immuno-Biological Laboratories have signed a new research agreement regarding Alzheimer's disease therapeutic drugs.
The agreement also includes investigation of the toxic amyloid ß42 (Aß42) using TransGenic’s model mouse, which will evaluate the drug’s effectiveness and efficacy and will also study the feasibility of developing it as a pharmaceutical product.
CanBas has signed a joint research agreement with imaging and information solutions provider Fujifilm regarding an anti-cancer drug using peptide.
The agreement enables CanBas to leverage its expertise in discovery studies of anticancer drug candidates using peptides to evaluate the efficacy of candidate compounds synthesised and designed by Dr Film.
Eloxx Pharmaceuticals has closed a $6m financing round in a series C venture financing led by Phil Frost, OPKO Health Inc. and Pontifax.
It brings the total gross proceeds raised by the company to $30m, has also seen participation from Korea Investment Partners, Dsc Investments LLC and Sevion Therapeutics Inc.
Minerva Neurosciences has announced a public offering of five million shares of its common stock along with a 30-day option to the underwriters to buy up to 750,000 additional shares to cover over-allotments, if any.
Proceeds will be used to support the ongoing clinical development of MIN-101, MIN-117, MIN-202 and MIN-301 and for other working capital and general corporate purposes.